Potassium Canrenoate in Brain-dead Organ Donors: Randomized Controlled Clinical Trial

Inclusion Criteria: * Men, women aged 18 years or older, * Encephalic death diagnosed either by 2 flat and areactive 30-minute electroencephalograms performed 4 hours apart or by a cerebral angioTDM objectifying a total cessation of intracranial circulation, * And from whom a removal of one or both kidneys is envisaged (within 6 hours or more), according to the procedures currently in force at the Agence de la Biomédecine, * Dosage of vasopressor agent amines that have not varied by more than 1 mg/h in the hour preceding inclusion and dose of vasopressor less than 7 mg / h at inclusion, * euvolemic donor patient at inclusion, * Benefiting from a Social Security affiliation scheme. * Signature of consent by a family member or the support person. Exclusion Criteria: * Patient having received potassium canrenoate in the 48 hours preceding inclusion in the study, * Patient on long-term mineralocorticoid receptor antagonist (eplerenone or spironolactone), * Having a serum potassium concentration\> 5.5 mmol / L on inclusion, * Contraindications to multi-organ removal (infectious, neoplastic causes, etc.), * Refusal of organ removal expressed by the patient (national register of refusals or reported by the family), * Probable inability to remove the kidneys: history of urine-renal disease, pre-existing chronic renal failure, morphological abnormalities of the kidneys, renal trauma, * Patients enrolled in another interventional drug trial, * Person with a contraindication to potas…